These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 17708548)

  • 1. The role of pelvic exenteration and reconstruction for treatment of advanced or recurrent gynecologic malignancies: Analysis of risk factors predicting recurrence and survival.
    Park JY; Choi HJ; Jeong SY; Chung J; Park JK; Park SY
    J Surg Oncol; 2007 Dec; 96(7):560-8. PubMed ID: 17708548
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pelvic Exenteration in Advanced Gynecologic Malignancies - Who Will Benefit?
    Egger EK; Liesenfeld H; Stope MB; Recker F; Döser A; Könsgen D; Marinova M; Hilbert T; Exner D; Ellinger J; Mustea A
    Anticancer Res; 2021 Jun; 41(6):3037-3043. PubMed ID: 34083295
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characteristics of gynecologic oncology patients in King Chulalongkorn Memorial Hospital - complications and outcome of pelvic exenteration.
    Oranratanaphan S; Termrungruanglert W; Sirisabya N
    Asian Pac J Cancer Prev; 2013; 14(4):2529-32. PubMed ID: 23725169
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pelvic Exenteration in Gynecologic Cancer: La Paz University Hospital Experience.
    Moreno-Palacios E; Diestro MD; De Santiago J; Hernández A; Zapardiel I
    Int J Gynecol Cancer; 2015 Jul; 25(6):1109-14. PubMed ID: 25853383
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mesorectal lymph node involvement and prognostic implications at total pelvic exenteration for gynecologic malignancies.
    Mourton SM; Chi DS; Sonoda Y; Alektiar KM; Venkatraman ES; Barakat RR; Abu-Rustum NR
    Gynecol Oncol; 2006 Mar; 100(3):533-6. PubMed ID: 16226800
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pelvic exenteration for recurrent gynecologic malignancy: survival and morbidity analysis of the 45-year experience at UCLA.
    Berek JS; Howe C; Lagasse LD; Hacker NF
    Gynecol Oncol; 2005 Oct; 99(1):153-9. PubMed ID: 16054678
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pelvic exenteration for gynecologic malignancies: The experience of a tertiary center from Greece.
    Haidopoulos D; Pergialiotis V; Aggelou K; Thomakos N; Alexakis N; Stamatakis E; Rodolakis A
    Surg Oncol; 2022 Mar; 40():101702. PubMed ID: 35065392
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pelvic exenteration for recurrent or persistent gynecologic malignancies: Clinical and histopathologic factors predicting recurrence and survival in a modern cohort.
    Straubhar AM; Chi AJ; Zhou QC; Iasonos A; Filippova OT; Leitao MM; Awowole IO; Abu-Rustum NR; Broach VA; Jewell EL; Sandhu JS; Sonoda Y
    Gynecol Oncol; 2021 Nov; 163(2):294-298. PubMed ID: 34518053
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pelvic exenteration for recurrent gynecologic malignancy: a study of 28 consecutive patients at a single institution.
    Jäger L; Nilsson PJ; Rådestad AF
    Int J Gynecol Cancer; 2013 May; 23(4):755-62. PubMed ID: 23407096
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pelvic exenteration: long-term oncological results in a series of 106 patients.
    De Wever I
    Acta Chir Belg; 2011; 111(5):282-7. PubMed ID: 22191128
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pelvic exenteration for gynecologic malignancies: Postoperative complications and oncologic outcomes.
    Romeo A; Gonzalez MI; Jaunarena J; Zubieta ME; Favre G; Tejerizo JC
    Actas Urol Esp (Engl Ed); 2018 Mar; 42(2):121-125. PubMed ID: 28911880
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overall survival after pelvic exenteration for gynecologic malignancy.
    Westin SN; Rallapalli V; Fellman B; Urbauer DL; Pal N; Frumovitz MM; Ramondetta LM; Bodurka DC; Ramirez PT; Soliman PT
    Gynecol Oncol; 2014 Sep; 134(3):546-51. PubMed ID: 25014540
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Feasibility of adjuvant chemotherapy after pelvic exenteration for gynecologic malignancies.
    Andikyan V; Khoury-Collado F; Sandadi S; Tew WP; O'Cearbhaill RE; Konner JA; Sonoda Y; Barakat RR; Chi DS; Abu-Rustum NR
    Int J Gynecol Cancer; 2013 Jun; 23(5):923-8. PubMed ID: 23698798
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pelvic exenterations for gynecological malignancies: a study of 36 cases.
    Kaur M; Joniau S; D'Hoore A; Van Calster B; Van Limbergen E; Leunen K; Penninckx F; Van Poppel H; Amant F; Vergote I
    Int J Gynecol Cancer; 2012 Jun; 22(5):889-96. PubMed ID: 22617477
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Five-year experience with combined operative and radiotherapeutic treatment of recurrent gynecologic tumors infiltrating the pelvic wall.
    Höckel M; Sclenger K; Hamm H; Knapstein PG; Hohenfellner R; Rösler HP
    Cancer; 1996 May; 77(9):1918-33. PubMed ID: 8646694
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pelvic Exenteration as Potential Cure and Symptom Relief in Advanced and Recurrent Gynaecological Cancer.
    Soeda S; Furukawa S; Sato T; Ueda M; Kamo N; Endo Y; Kojima M; Nomura S; Kataoka M; Fujita S; Endo H; Takahashi T; Watanabe T; Yamada H; Fujimori K
    Anticancer Res; 2019 Oct; 39(10):5631-5637. PubMed ID: 31570460
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The value of 18F-FDG PET/CT in recurrent gynecologic malignancies prior to pelvic exenteration.
    Burger IA; Vargas HA; Donati OF; Andikyan V; Sala E; Gonen M; Goldman DA; Chi DS; Schöder H; Hricak H
    Gynecol Oncol; 2013 Jun; 129(3):586-592. PubMed ID: 23369941
    [TBL] [Abstract][Full Text] [Related]  

  • 18. R0 Resection in Recurrent Gynecologic Malignancy: Pelvic Exenteration and Beyond.
    Xu C; Garda AE; Kumar A
    Curr Treat Options Oncol; 2023 Apr; 24(4):262-273. PubMed ID: 36847987
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trends and current aspects of reconstructive surgery for gynecological cancers.
    Loverro M; Aloisi A; Tortorella L; Aletti GD; Kumar A
    Int J Gynecol Cancer; 2024 Mar; 34(3):426-435. PubMed ID: 38438169
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of preoperative MR imaging in the evaluation of patients with persistent or recurrent gynaecological malignancies before pelvic exenteration.
    Donati OF; Lakhman Y; Sala E; Burger IA; Vargas HA; Goldman DA; Andikyan V; Park KJ; Chi DS; Hricak H
    Eur Radiol; 2013 Oct; 23(10):2906-15. PubMed ID: 23652852
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.